Elekta AB Unsponsored American Depositary Receipt

Elekta AB Unsponsored American Depositary Receipt represents shares in Elekta AB, a Swedish medical technology company that develops and provides advanced clinical solutions for the treatment of cancer and brain disorders. Through its specialized radiotherapy, brachytherapy, and neurosurgery products—including the Elekta Unity system for real-time MRI-guided radiation therapy and the Leksell Gamma Knife for precision radiosurgery—Elekta serves oncology departments, clinics, and hospitals globally. The company’s portfolio also encompasses oncology software solutions designed to support tailored treatments across radiotherapy, surgery, chemotherapy, and immunotherapy. With a presence in markets worldwide, Elekta AB plays a significant role in advancing precision medicine and improving cancer care outcomes for patients. The American Depositary Receipt structure enables U.S. investors to access Elekta AB shares in the U.S. over-the-counter market, with each ADR typically representing one ordinary share. As an unsponsored ADR trading on the OTC Pink marketplace, it provides a means for international ownership, albeit with fewer regulatory reporting requirements or direct involvement from Elekta AB itself.